ABBV vs NRIX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
ABBV is the larger of the two ($509.92B market cap): the incumbent the market prices for continued execution (17.79x forward earnings, beta 0.19). NRIX is the smaller challenger ($1.43B), still expected to post a loss next year: more room to run, but more to prove. On the numbers, ABBV leads on both counts: faster expected revenue growth (9% vs -83%) and expected profits next year, which NRIX does not have. The case for NRIX rests on its own driver (Bexobrutideg registrational path): if you believe in that, NRIX fits; if you believe in what the numbers show today, ABBV does.
ABBV vs NRIX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ABBV | NRIX | What it tells you |
|---|---|---|---|
| Market cap | $509.92B | $1.43B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 17.79 | -10.24 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 49.57 | 5.38 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.19 | 1.78 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 87% of range | 0% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how ABBV and NRIX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and NRIX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and NRIX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AbbVie (ABBV) do?
AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.
What does Nurix Therapeutics (NRIX) do?
Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Its lead program, bexobrutideg (NX-5948), is an oral, brain-penetrant degrader of BTK being studied in chronic lymphocytic leukemia and other blood cancers, with a registrational Phase 2 DAYBreak CLL-201 study supporting a potential accelerated approval and a Phase 3 DAYBreak CLL-306 study, comparing it with pirtobrutinib in about 620 patients, that enrolled its first patient by October 2026. Beyond bexobrutideg, Nurix has wholly owned programs including zelebrudomide (NX-2127) and the CBL-B inhibitor NX-1607, plus partnered discovery work with Gilead Sciences, Sanofi, and Pfizer where it retains options to co-develop and share profits.
ABBV vs NRIX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
- NRIX drivers: Bexobrutideg registrational path; Roche collaboration.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For NRIX, as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials.
ABBV or NRIX: which should you pick?
If the story you believe is ABBV's (Skyrizi and Rinvoq replacing Humira faster than expected), ABBV is the more direct way to own it; if it is NRIX's (Bexobrutideg registrational path), NRIX is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and NRIX guides.
ABBV vs NRIX: the full fundamentals
ABBV. The gap between the trailing GAAP P/E (about 50x, inflated by non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 17.8x illustrates why analysts and management prefer adjusted metrics: upfront licensing and milestone payments depress reported earnings without reducing cash generation. The trailing multiple has fallen from about 80x in October as a strong Q3 GAAP quarter (about $4.2 billion of net income) replaced weaker ones, while the forward multiple has drifted up with the share price. The 26 covering analysts have a buy consensus and a mean target near $316.
NRIX. Nurix's trailing P/E of about 5x is an artifact of one quarter: the Roche upfront payment produced roughly $550 million of net income in the August 2026 quarter, and analysts expect losses to resume in fiscal 2027. The market still values it on pipeline potential, partnership economics, and cash runway. With about $1.1 billion of cash against a market value near $1.4 billion after the Sanofi-driven selloff, investors are now assigning only about $0.3 billion to bexobrutideg and the rest of the pipeline, which is funded into the second half of 2029; dilution risk has eased while clinical risk remains. The 14 analysts Yahoo Finance tracks carry a mean target near $33.50, though several were set before the Sanofi news.
Headline figures (approximate, November 2026): ABBV shows revenue (ttm) ~$66.0 billion (Q3 2026 ~$17.4B, up ~10% YoY), adjusted eps Q3 2026 $3.82 vs $3.76 estimate; FY2026 consensus ~$13.98; FY2027 consensus ~$16.22, gaap net income (ttm) ~$10.3 billion (GAAP EPS ~$5.82, depressed by acquired IPR and D), margins (ttm) ~74% gross, ~37% operating, ~16% net; NRIX shows revenue (q3 fy2026, quarter ended aug 31 2026) ~$673.1 million (~$653.2 million Roche license revenue), net income (q3 fy2026) ~$549.8 million (~$4.73 per share vs ~$5.02 consensus), revenue (ttm) ~$702 million, net income (ttm) ~$295 million.
The bottom line: ABBV vs NRIX
ABBV and NRIX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ABBV and NRIX exposure against your real portfolio. It is not an investment adviser.
Wondering how ABBV or NRIX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about AbbVie
Ask Walnut's AI anything about ABBV and see how it fits what you own.
FAQ
What is the difference between ABBV and NRIX?
+
AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ABBV or NRIX the better stock?
+
Neither is universally better. ABBV is the larger incumbent; NRIX is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ABBV or NRIX?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ABBV and NRIX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ABBV vs NRIX?
+
ABBV: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, about $81.3 billion as of September 2026 against about $10.8 billion of cash, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. GAAP earnings are depressed by acquired research charges, so the dividend exceeds trailing GAAP net income (a payout ratio near 117% of trailing GAAP EPS of about $5.82), and it is covered by cash flow rather than reported profit. Integrating acquisitions such as Apogee Therapeutics introduces execution risk, the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles, and after a 26% gain in 2026 the shares trade near their highs, though the mean analyst target has risen to about $316. NRIX: As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. The roughly $1.1 billion cash position eases near-term funding pressure. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected registrational path could sharply reduce the valuation. Partner risk is real, as November 2026 showed: Sanofi's decision to end SAR448272 cut about $455 million of potential milestones and sent the shares down about 38% in a day, and Wells Fargo said it had attributed about $400 million of value to the program. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and remaining milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABBV or NRIX; figures are approximate and dated (as of November 2026). Verify current data before investing.